Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-3276-2026

Philips IntraSight Plus REF: 797423 and 797417 100-120v-220-240v,50/60hZ, 1000 VA Recall

Philips IntraSight Plus REF: 797423 and 797417 100-120v-220-240v,50/60hZ, 1000 VA

FDA recall Class II

Ongoing

FDA lists this Class II recall for Philips IntraSight Plus REF: 797423 and 797417 100-120v-220-240v,50/60hZ, 1000 VA. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-3276-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Aug 6, 2026
FDA report date
Oct 7, 2026
Quantity in commerce
19 systems
Distribution
See key details
FDA cause
Software Design Change

What is being recalled?

Philips IntraSight Plus REF: 797423 and 797417 100-120v-220-240v,50/60hZ, 1000 VA

Affected model & UDI checker

Search the exact identifiers published for Z-3276-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
797423Philips IntraSight Plus REF: 797423 and 797417 100-120v-220-240v,50/60hZ, 1000 VACheck source noticeNot specified
797417Philips IntraSight Plus REF: 797423 and 797417 100-120v-220-240v,50/60hZ, 1000 VACheck source noticeNot specified
FDA code information

UDI: REF: 797423:(01)00845225012946/REF:797417: (01)00845225012939 all Philips IntraSight Plus Systems with Software Version 6.0.4

View the original FDA recall notice

Why was this product recalled?

Software system may associate image data from one patient with another patient's record, potentially resulting in incorrect diagnosis or treatment.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Volcano Corp take?

On August 6, 2026, Philips issued a Urgent Medical Device Correction to affected consignees. Philips ask consignees to take the following actions: 1. Contact your local Philips Service representative in advance of any changes to the worklist provider, Azurion software, interface configuration, or hospital IT environment, as such changes may affect the Study ID field. Your Philips Service representative will help evaluate any impact and/or reverify as applicable. Otherwise, you may continue to use the device in accordance with the intended use. 2. Please circulate this notice to all users of the IntraSight Plus so they are aware of the issue and associated hazard / harm. Philips also encourages all customers to post this letter on or near the system until Philips has updated its software.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology